Phibro Animal Health (PAHC) Change in Accured Expenses (2013 - 2026)
Phibro Animal Health's (PAHC) quarterly Change in Accured Expenses came in at $361000.0 in Q1 2026, up 281.41% year-on-year from $94649.5 in Q1 2025, and down 96.73% quarter-over-quarter from $11.0 million in Q4 2025.
Phibro Animal Health (PAHC) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Phibro Animal Health's Change in Accured Expenses history runs 14 years deep, the most recent figure standing at $361000.0 for Q1 2026.
- On a quarterly basis, Change in Accured Expenses rose 281.41% year-over-year to $361000.0 in Q1 2026; TTM through Mar 2026 was $23.8 million, a 21.48% decrease from a year earlier, with the FY2025 full-year figure at $47.2 million, up 286.9% from the prior year.
- Change in Accured Expenses declined to $361000.0 in Q1 2026 per PAHC's latest filing, from $11.0 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $26.1 million in Q2 2025 and bottomed at -$13.7 million in Q3 2025.
- The 5-year median for Change in Accured Expenses is $361000.0 (2026), against an average of $3.3 million.
- Across the five-year window, Change in Accured Expenses soared 1357.99% in 2024 and slumped 288.42% in 2025, its largest moves.
- Year by year, Change in Accured Expenses stood at $6.0 million in 2022, then surged by 36.38% to $8.2 million in 2023, then soared by 202.8% to $24.8 million in 2024, then tumbled by 55.48% to $11.0 million in 2025, then slumped by 96.73% to $361000.0 in 2026.
- Per Business Quant, the three latest PAHC Change in Accured Expenses figures stand at $361000.0 (Q1 2026), $11.0 million (Q4 2025), and -$13.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Phibro Animal Health | 1.43 Bn | 1.35 Bn | 125.68 Mn | 361,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 361,000.00 |
| Mar 31, 2026 | 361,000.00 |
| Dec 31, 2025 | 11.03 Mn |
| Dec 31, 2025 | 11.03 Mn |
| Sep 30, 2025 | -13.69 Mn |
| Sep 30, 2025 | -13.69 Mn |
| Jun 30, 2025 | 26.12 Mn |
| Jun 30, 2025 | 26.12 Mn |
| Mar 31, 2025 | -199,000.00 |
| Mar 31, 2025 | -199,000.00 |
| Dec 31, 2024 | 24.77 Mn |
| Dec 31, 2024 | 24.77 Mn |
| Sep 30, 2024 | -3.52 Mn |
| Sep 30, 2024 | -3.52 Mn |
| Jun 30, 2024 | 9.28 Mn |
| Jun 30, 2024 | 9.28 Mn |
| Mar 31, 2024 | 530,000.00 |
| Mar 31, 2024 | 530,000.00 |
| Dec 31, 2023 | 8.18 Mn |
| Dec 31, 2023 | 8.18 Mn |